Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation

被引:9
作者
Plitt, Anna [1 ]
Ruff, Christian T. [2 ]
Giugliano, Robert P. [2 ]
机构
[1] Mt Sinai Hosp, Dept Internal Med, One Gustave L Levy Pl, New York, NY 10029 USA
[2] Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, 350 Longwood Ave,1st Floor Off, Boston, MA 02115 USA
关键词
Atrial fibrillation; NOAC; Dabigatran; Rivaroxaban; Apixaban; Edoxaban; FACTOR XA INHIBITOR; DIRECT THROMBIN INHIBITOR; DABIGATRAN ETEXILATE; RENAL-FUNCTION; RISK-FACTORS; WARFARIN; RIVAROXABAN; REVERSAL; CARDIOVERSION; APIXABAN;
D O I
10.1016/j.hoc.2016.05.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
For more than 50 years, vitamin K antagonists (VKAs) have been the standard of care for treatment of atrial fibrillation (AF). However, the numerous limitations of VKAs have led to the development of non-VKA oral anticoagulants (NOACs). There are 4 NOACs currently approved for prevention of thromboembolism in patients with nonvalvular AF. This article provides an overview of AF, summarizes basic properties of NOACs, and reviews the landmark trials. Current data on use of NOACs in special populations and specific clinical scenarios are also presented. Lastly, recommendations from experts on controversial topics of bleeding management and reversal are described.
引用
收藏
页码:1019 / +
页数:17
相关论文
共 56 条
[1]  
[Anonymous], SAV ED PACK INS
[2]  
[Anonymous], EUROPACE 2015
[3]  
[Anonymous], EL AP PACK INS
[4]  
[Anonymous], XARALTO RIVAROXABAN
[5]  
[Anonymous], PRAD DAB ET PACK INS
[6]   Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban [J].
Ansell, Jack E. ;
Bakhru, Sasha H. ;
Laulicht, Bryan E. ;
Steiner, Solomon S. ;
Grosso, Michael ;
Brown, Karen ;
Dishy, Victor ;
Noveck, Robert J. ;
Costin, James C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (22) :2141-2142
[7]   Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran [J].
Beasley, B. Nhi ;
Unger, Ellis F. ;
Temple, Robert .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1788-1790
[8]   Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation [J].
Cappato, Riccardo ;
Ezekowitz, Michael D. ;
Klein, Allan L. ;
Camm, A. John ;
Ma, Chang-Sheng ;
Le Heuzey, Jean-Yves ;
Talajic, Mario ;
Scanavacca, Mauricio ;
Vardas, Panos E. ;
Kirchhof, Paulus ;
Hemmrich, Melanie ;
Lanius, Vivian ;
LingMeng, Isabelle ;
Wildgoose, Peter ;
van Eickels, Martin ;
Hohnloser, Stefan H. .
EUROPEAN HEART JOURNAL, 2014, 35 (47) :3346-3355
[9]   Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range [J].
Connolly, Stuart J. ;
Pogue, Janice ;
Eikelboom, John ;
Flaker, Gregory ;
Commerford, Patrick ;
Franzosi, Maria Grazia ;
Healey, Jeffrey S. ;
Yusuf, Salim .
CIRCULATION, 2008, 118 (20) :2029-2037
[10]   The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study [J].
Connolly, Stuart J. ;
Wallentin, Lars ;
Ezekowitz, Michael D. ;
Eikelboom, John ;
Oldgren, Jonas ;
Reilly, Paul A. ;
Brueckmann, Martina ;
Pogue, Janice ;
Alings, Marco ;
Amerena, John V. ;
Avezum, Alvaro ;
Baumgartner, Iris ;
Budaj, Andrzej J. ;
Chen, Jyh-Hong ;
Dans, Antonio L. ;
Darius, Harald ;
Di Pasquale, Giuseppe ;
Ferreira, Jorge ;
Flaker, Greg C. ;
Flather, Marcus D. ;
Franzosi, Maria Grazia ;
Golitsyn, Sergey P. ;
Halon, David A. ;
Heidbuchel, Hein ;
Hohnloser, Stefan H. ;
Huber, Kurt ;
Jansky, Petr ;
Kamensky, Gabriel ;
Keltai, Matyas ;
Kim, Sung Soon ;
Lau, Chu-Pak ;
Le Heuzey, Jean-Yves ;
Lewis, Basil S. ;
Liu, Lisheng ;
Nanas, John ;
Omar, Razali ;
Pais, Prem ;
Pedersen, Knud E. ;
Piegas, Leopoldo S. ;
Raev, Dimitar ;
Smith, Pal J. ;
Talajic, Mario ;
Tan, Ru San ;
Tanomsup, Supachai ;
Toivonen, Lauri ;
Vinereanu, Dragos ;
Xavier, Denis ;
Zhu, Jun ;
Wang, Susan Q. ;
Duffy, Christine O. .
CIRCULATION, 2013, 128 (03) :237-243